Stockreport

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Precision BioSciences, Inc.  (DTIL) 
Last precision biosciences, inc. earnings: 11/12 07:15 am Check Earnings Report
PDF - PBGENE-HBV, the first and only clinical stage gene editing therapy for chronic hepatitis B –- Repeat dosing of PBGENE-HBV supported by definitive preclinical safety an [Read more]